These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22581754)

  • 21. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla.
    Sicotte NL; Voskuhl RR; Bouvier S; Klutch R; Cohen MS; Mazziotta JC
    Invest Radiol; 2003 Jul; 38(7):423-7. PubMed ID: 12821856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
    McFarland HF; Frank JA; Albert PS; Smith ME; Martin R; Harris JO; Patronas N; Maloni H; McFarlin DE
    Ann Neurol; 1992 Dec; 32(6):758-66. PubMed ID: 1471866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI.
    Wu Y; Warfield SK; Tan IL; Wells WM; Meier DS; van Schijndel RA; Barkhof F; Guttmann CR
    Neuroimage; 2006 Sep; 32(3):1205-15. PubMed ID: 16797188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Magnetic resonance in the diagnosis and treatment of multiple sclerosis].
    Rovira Cañellas A
    Neurologia; 2000; 15(7):288-302. PubMed ID: 11075577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
    Stone LA; Frank JA; Albert PS; Bash C; Smith ME; Maloni H; McFarland HF
    Ann Neurol; 1995 May; 37(5):611-9. PubMed ID: 7755356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.
    Moraal B; Meier DS; Poppe PA; Geurts JJ; Vrenken H; Jonker WM; Knol DL; van Schijndel RA; Pouwels PJ; Pohl C; Bauer L; Sandbrink R; Guttmann CR; Barkhof F
    Radiology; 2009 Feb; 250(2):506-14. PubMed ID: 19037018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toward Quantifying the Prevalence, Severity, and Cost Associated With Patient Motion During Clinical MR Examinations.
    Andre JB; Bresnahan BW; Mossa-Basha M; Hoff MN; Smith CP; Anzai Y; Cohen WA
    J Am Coll Radiol; 2015 Jul; 12(7):689-95. PubMed ID: 25963225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI: role in optimising treatment.
    Traboulsee A
    J Neurol; 2004 Sep; 251 Suppl 5():v36-v41. PubMed ID: 15549354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility.
    Guttmann CR; Kikinis R; Anderson MC; Jakab M; Warfield SK; Killiany RJ; Weiner HL; Jolesz FA
    J Magn Reson Imaging; 1999 Apr; 9(4):509-18. PubMed ID: 10232508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis.
    Broderick JP; Narayan S; Gaskill M; Dhawan AP; Khoury J
    J Neuroimaging; 1996 Jan; 6(1):36-43. PubMed ID: 8555662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis.
    Paty DW; Li DK; Oger JJ; Kastrukoff L; Koopmans R; Tanton E; Zhao GJ
    Ann Neurol; 1994; 36 Suppl():S95-6. PubMed ID: 8017896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials.
    Paty DW; McFarland H
    J Neurol Neurosurg Psychiatry; 1998 May; 64 Suppl 1():S47-51. PubMed ID: 9647285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardisation and optimisation of magnetic resonance techniques for multicentre studies.
    Tofts PS
    J Neurol Neurosurg Psychiatry; 1998 May; 64 Suppl 1():S37-43. PubMed ID: 9647283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lesion volume measurement in multiple sclerosis: how important is accurate repositioning?
    Gawne-Cain ML; Webb S; Tofts P; Miller DH
    J Magn Reson Imaging; 1996; 6(5):705-13. PubMed ID: 8890007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of imprecise repositioning on lesion volume measurements in patients with multiple sclerosis.
    Filippi M; Marcianò N; Capra R; Rocca MA; Prandini F; Gasparotti R; Horsfield MA; Comi G
    Neurology; 1997 Jul; 49(1):274-6. PubMed ID: 9222208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The NAIMS cooperative pilot project: Design, implementation and future directions.
    Oh J; Bakshi R; Calabresi PA; Crainiceanu C; Henry RG; Nair G; Papinutto N; Constable RT; Reich DS; Pelletier D; Rooney W; Schwartz D; Tagge I; Shinohara RT; Simon JH; Sicotte NL;
    Mult Scler; 2018 Nov; 24(13):1770-1772. PubMed ID: 29106329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using diffusion-weighted MRI in multicenter clinical trials for multiple sclerosis.
    Horsfield MA
    J Neurol Sci; 2001 May; 186 Suppl 1():S51-4. PubMed ID: 11334990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adversarial Bayesian Optimization for Quantifying Motion Artifact Within MRI.
    Butskova A; Juhl R; Zukić D; Chaudhary A; Pohl KM; Zhao Q
    Predict Intell Med; 2021 Oct; 12928():83-92. PubMed ID: 35749100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Chard DT
    Neurology; 2024 Mar; 102(5):e209246. PubMed ID: 38335501
    [No Abstract]   [Full Text] [Related]  

  • 40. Patient Motion During Clinical MR Examinations, Beyond the Economic Burden.
    Nabavizadeh SA
    J Am Coll Radiol; 2016 Mar; 13(3):235. PubMed ID: 26747721
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.